Q2 EPS Estimates for HCA Healthcare Lifted by Analyst

HCA Healthcare, Inc. (NYSE:HCA - Free Report) - Leerink Partnrs lifted their Q2 2025 EPS estimates for HCA Healthcare in a research note issued to investors on Monday, April 28th. Leerink Partnrs analyst W. Mayo now forecasts that the company will post earnings per share of $6.51 for the quarter, up from their prior forecast of $6.37. The consensus estimate for HCA Healthcare's current full-year earnings is $24.98 per share. Leerink Partnrs also issued estimates for HCA Healthcare's Q3 2025 earnings at $5.84 EPS, Q4 2025 earnings at $7.01 EPS, FY2025 earnings at $25.82 EPS, Q1 2026 earnings at $7.27 EPS, Q2 2026 earnings at $7.40 EPS, Q3 2026 earnings at $6.79 EPS, Q4 2026 earnings at $8.56 EPS, FY2026 earnings at $30.02 EPS, FY2027 earnings at $34.11 EPS, FY2028 earnings at $38.44 EPS and FY2029 earnings at $43.24 EPS.

Other equities analysts have also recently issued research reports about the stock. StockNews.com raised shares of HCA Healthcare from a "hold" rating to a "buy" rating in a research report on Monday, April 28th. Guggenheim started coverage on HCA Healthcare in a research note on Wednesday, April 9th. They set a "neutral" rating for the company. Cantor Fitzgerald reissued an "overweight" rating and set a $405.00 price objective on shares of HCA Healthcare in a research report on Monday, January 27th. Robert W. Baird reiterated a "neutral" rating and set a $336.00 price target (down previously from $396.00) on shares of HCA Healthcare in a report on Tuesday, April 15th. Finally, Bank of America decreased their price objective on shares of HCA Healthcare from $380.00 to $370.00 and set a "buy" rating for the company in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, HCA Healthcare has a consensus rating of "Moderate Buy" and a consensus price target of $381.13.

HCA Healthcare Trading Up 1.5 %

NYSE:HCA traded up $5.07 on Wednesday, reaching $348.11. 802,331 shares of the company's stock were exchanged, compared to its average volume of 1,400,124. The company has a quick ratio of 0.97, a current ratio of 1.08 and a debt-to-equity ratio of 69.07. The firm has a market capitalization of $85.71 billion, a price-to-earnings ratio of 15.84, a price-to-earnings-growth ratio of 1.10 and a beta of 1.48. The business has a fifty day moving average of $331.79 and a 200-day moving average of $330.21. HCA Healthcare has a 52-week low of $289.98 and a 52-week high of $417.14.

HCA Healthcare (NYSE:HCA - Get Free Report) last announced its earnings results on Friday, April 25th. The company reported $6.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.75 by $0.70. The company had revenue of $18.32 billion for the quarter, compared to analyst estimates of $18.26 billion. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. The firm's quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.36 earnings per share.

HCA Healthcare Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 16th will be issued a $0.72 dividend. The ex-dividend date is Monday, June 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.83%. HCA Healthcare's payout ratio is 12.81%.

Insiders Place Their Bets

In other news, SVP Jennifer Berres sold 9,533 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $322.59, for a total transaction of $3,075,250.47. Following the completion of the sale, the senior vice president now owns 15,412 shares in the company, valued at $4,971,757.08. This represents a 38.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is currently owned by insiders.

Institutional Trading of HCA Healthcare

A number of institutional investors have recently modified their holdings of the business. Norges Bank purchased a new position in HCA Healthcare in the 4th quarter valued at approximately $840,286,000. GAMMA Investing LLC raised its stake in shares of HCA Healthcare by 40,527.3% during the 1st quarter. GAMMA Investing LLC now owns 1,703,907 shares of the company's stock worth $5,887,850,000 after buying an additional 1,699,713 shares during the last quarter. Royal London Asset Management Ltd. grew its position in shares of HCA Healthcare by 62.0% in the fourth quarter. Royal London Asset Management Ltd. now owns 1,500,786 shares of the company's stock valued at $450,461,000 after purchasing an additional 574,239 shares during the last quarter. Barclays PLC raised its position in shares of HCA Healthcare by 85.7% during the 4th quarter. Barclays PLC now owns 1,061,891 shares of the company's stock worth $318,727,000 after purchasing an additional 489,916 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in HCA Healthcare by 120.1% during the fourth quarter. Principal Financial Group Inc. now owns 873,775 shares of the company's stock worth $262,264,000 after buying an additional 476,756 shares in the last quarter. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.